Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: Plunkett Research, Ltd.
$99.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Medtronic, Inc announces people with type 2 Diabetes achieve superior outcomes with insulin pumps vs. multiple daily injections


Wednesday, 2 Jul 2014 07:15pm EDT 

Medtronic, Inc:Says that the results of the OpT2mise trial, which showed that MiniMed insulin pumps safely achieve better glucose control for people with insulin-requiring type 2 diabetes than multiple daily injections.Says while the benefits of insulin pump therapy for people with type 1 diabetes are well proven, this is the largest global study to evaluate the comparative efficacy of insulin pump therapy versus multiple daily insulin injections in people with type 2 diabetes with poor glycemic control.Says In the OpT2mise trial, those using insulin pumps achieved a mean A1C (average blood glucose) reduction of 1.1 percent compared to only a 0.4 percent reduction by those using multiple daily injections.This improvement in glucose control was achieved without any episodes of severe hypoglycemia.In addition, those in the insulin pump group lowered the total daily dose of insulin by more than 20 percent.There was no difference in weight gain between the two groups.Reducing A1C is critical for people with diabetes because even small percent drops aid significantly in preventing complications such as eye disease, kidney disease, nerve damage and heart attacks. 

Company Quote

63.37
0.66 +1.05%
23 Jul 2014